Clinical trial

A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children…

NCT00000653 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed

Key facts

NCT number NCT00000653
Title A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT
Official title A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID), NIH
Collaborators Hoffmann-La Roche Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions HIV Infections
Intervention type Drug
Interventions Zalcitabine
Enrollment 140
Completion Jun 1, 1995
First posted Aug 31, 2001
Last update posted Oct 27, 2021
Countries Puerto Rico, United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies